Seattle Gummy Company (SGC) is an R&D focused developer and manufacturer of functional gummy and pharmaceutical gummy products. SGC specializes in formulating high-loading functional gummy and pharmaceutical gummy products combining the wealth of the in-house knowledge in pharmaceutics, organic chemistry, natural product chemistry, western medicine, and herbal medicine. SGC’s formulas are rooted in SGC scientists’ deep understanding of human physiological needs and backed by research and science. The company boosts a strong and continuously expanding intellectual property portfolio on gummy sciences and a robust product pipeline. SGC Functional Gummies are sold under Mocca Shots®, Slumber Shots®, Immunity Shots®, ACV Shots®, Energy Qube™, and Seattle Beauty® brands on all major e-commerce sites as well as tens of thousands of retails stores.SGC's pharmaceutical gummy pipeline features all major OTC drugs as well as several D2C Rx drugs. In 2020, SGC received the first IND approval from FDA on a gummy drug formulations. The company plans to launch the commercial gummy pharmaceutical products in 2024.

Lead R&D activities including new technology and new product development; crafted, created and managing a large IP portfolio including both patents and trademarks to protect and strengthen the company business activities; created new product lines and shepherded the products from concept, bench study, pilot production, academic animal trial, field trial to full commercial sales; lead marketing and sales efforts in Asian, Europe and North America. Benemilk Ltd is a joint venture company by the Finnish Raisio Group and Intellectual Ventures. The joint venture aims to commercialize the Benemilk® technology for global markets and to expand and strengthen the intellectual property portfolio related to the Benemilk® and PrimaFat® invention.

Director, Chemistry and MaterialsInvention capital investment; IV spinoff formation and portfolio companies management; IP and technology acquisition and commercialization; managing IP strategies for joint ventures and corporate partnerships; IP assets evaluation, due diligence, acquisition, licensing, and monetization; patent portfolio strategy and management; patent filing strategies; patentability and freedom to operate analysis; IP landscape analysis and whitespace analysis; IP due diligence; patentability searches; invention write-up; patent preparation and prosecution; managing trademark preparation and prosecution; inventor network management, development and training; and managing IP aspects of the R&D projects and research collaborations.

Client counseling on IP strategy; patent preparation and prosecution in the fields of chemistry, pharmaceutics, therapeutic methods, biotechnology, medical devices, polymers, material sciences, and nanotechnology; Design patent preparation and prosecution; patent validity and infringement analyses; patentability opinions; client counseling and case management; intellectual property due diligence; trademark searches and availability opinions; trademark registrations, oppositions, and cancellations; and copyright registration and management.

Formation of the pharmaceutical start-up, negotiating technology licenses of the "thermogel" patent portfolio with Pacific Northwest National Lab, negotiating with venture capital firms for the purpose of obtaining funding for the company, and negotiating with pharmaceutical companies in China for collaboration opportunities.

Patent preparation and prosecution, intellectual property due diligence, and IP litigation.

Synthesis of star-burst dendrimers for pre-targeting cancer therapy, conjugation of monoclonal antibodies with targeting agents, testing internalization of monoclonal antibodies on prostate cancer cells, testing the conjugated antibodies in animal models of cancer.

Legislative matters relating to biotechnology, health care, Hanford nuclear waste clean-up, and energy resource.

Synthesis of small organic molecules in search for pharmaceutical lead compounds.